Home » Authors » Jim Shrine

Articles by Jim Shrine

Cytos, Novartis Enter Potential $500M Deal On Nicotine Vaccine

April 26, 2007

BioMarin Raises $324.9M Via Offering Of Convertible Notes

April 25, 2007

Halozyme Brings In $32.1M Via Private Deal With New River

April 25, 2007

Halozyme Brings In $32.1M Via Private Deal With New River

April 25, 2007

BioMarin Raises $324.9M Via Offering Of Convertible Notes

April 25, 2007

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion

April 24, 2007

MedImmune Inc., which officially put itself up for sale less than two weeks ago, agreed Monday to be acquired by AstraZeneca plc for $15.2 billion. (BioWorld Today)

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion

April 24, 2007

MedImmune Inc., which officially put itself up for sale less than two weeks ago, agreed Monday to be acquired by AstraZeneca plc for $15.2 billion. (BioWorld Today)

Altus Raises $88.5M Publicly To Fund Protein Therapeutics

April 20, 2007

Altus Raises $88.5M Publicly To Fund Protein Therapeutics

April 20, 2007

Cel-Sci Raises $15M, Plans To Move MultiKine Into Phase III

April 19, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...